Major Study Finds No Link Between Antidepressants in Pregnancy and Autism or ADHD in Children

A major international study has found no evidence that antidepressant use before or during pregnancy increases the risk of neurodevelopmental disorders such as autism or ADHD in children. The comprehensive review, published in The Lancet Psychiatry on May 14, analyzed data from 37 high-quality studies involving more than 648,000 pregnancies with antidepressant exposure and nearly 25 million without.

The research, led by scientists from the University of Hong Kong and global institutions, examined outcomes including ADHD, autism spectrum disorder (ASD), intellectual disabilities, motor disorders, and speech or language delays. After adjusting for factors such as maternal mental health, family genetics, and antidepressant dosage, the study found no causal link between antidepressant use and these conditions in offspring.

While the analysis initially showed a small increase in risk for ADHD and autism when antidepressants were used during pregnancy, this association disappeared once other contributing factors were accounted for. The findings underscore the importance of considering genetic and environmental influences rather than medication alone.

Key Findings from the Study

• No causal link between antidepressant use before or during pregnancy and ADHD or autism in children.
• Initial small increase in risk for neurodevelopmental disorders was eliminated after adjusting for confounding factors.
• Study included 37 high-quality studies covering over 648,000 pregnancies with antidepressant exposure.
• Researchers accounted for maternal mental health, genetics, dosage, and timing of antidepressant use.
• Study plan was pre-registered in PROSPERO for transparency and research quality.

According to the American College of Obstetricians and Gynecologists (ACOG), approximately 10% of pregnant individuals experience depression. Untreated depression poses serious risks to both the pregnant person and their baby, making antidepressants a commonly prescribed treatment during and after pregnancy.

Despite the well-established safety and efficacy of antidepressants, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. has discouraged the use of selective serotonin reuptake inhibitors (SSRIs), a widely prescribed class of antidepressants. The new findings aim to address misinformation surrounding antidepressant use during pregnancy.

Why the Findings Matter

The study provides critical evidence to counter concerns about the safety of antidepressants during pregnancy. By demonstrating that genetic and environmental factors likely play a larger role in neurodevelopmental disorders, the research supports the continued use of antidepressants when medically necessary. It also highlights the need for balanced discussions about the risks and benefits of treatment during pregnancy.

"The findings suggest that the small increased risk observed in some studies is likely due to underlying factors rather than the medication itself." — Study authors, The Lancet Psychiatry